{"id":243484,"date":"2026-09-02T01:06:23","date_gmt":"2026-09-02T06:06:23","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2026\/09\/when-egfrmutant-nsclc-becomes-sclc-can-immunotherapy-become-relevant-again"},"modified":"2026-09-02T01:06:23","modified_gmt":"2026-09-02T06:06:23","slug":"when-egfrmutant-nsclc-becomes-sclc-can-immunotherapy-become-relevant-again","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2026\/09\/when-egfrmutant-nsclc-becomes-sclc-can-immunotherapy-become-relevant-again","title":{"rendered":"When EGFRMutant NSCLC Becomes SCLC: Can Immunotherapy Become Relevant Again?"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/when-egfrmutant-nsclc-becomes-sclc-can-immunotherapy-become-relevant-again.webp\"><\/a><\/p>\n<p>All included patients had histologically confirmed EGFR-mutant lung cancer followed by biopsy-proven SCLC transformation. Fifty-nine patients were identified, making this one of the larger multicenter real-world datasets examining this specific resistance phenotype.<\/p>\n<p>The median age was 57.8 years, and 76.3% of patients carried an EGFR exon 19 deletion.<\/p>\n<p>Most patients had initially presented with metastatic disease, and 57 of 59 had received first-line EGFR-TKI therapy. Median progression-free survival on initial EGFR-targeted therapy was 14 months, while the median interval from metastatic diagnosis to histologic SCLC transformation was 22 months.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>All included patients had histologically confirmed EGFR-mutant lung cancer followed by biopsy-proven SCLC transformation. Fifty-nine patients were identified, making this one of the larger multicenter real-world datasets examining this specific resistance phenotype. The median age was 57.8 years, and 76.3% of patients carried an EGFR exon 19 deletion. Most patients had initially presented with metastatic [\u2026]<\/p>\n","protected":false},"author":662,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11],"tags":[],"class_list":["post-243484","post","type-post","status-publish","format-standard","hentry","category-biotech-medical"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/243484","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/662"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=243484"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/243484\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=243484"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=243484"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=243484"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}